tions and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Sequencing of subcloned PCR products facilitates earlier detection of BCR-ABL1
Single-point mutations within the kinase domain (KD) of BCR-ABL1 constitute the most frequent cause of acquired resistance to tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukemia (CML). Particularly, worrisome is the development of the BCR-ABL1 T315I mutation, which affects a highly conserved 'gatekeeper' threonine residue near the ABL catalytic domain, which causes steric hindrance that precludes the binding of TKIs to the ABL kinase. 1 As a result, BCR-ABL1 T315I confers resistance to imatinib and second generation inhibitors (dasatinib and nilotinib), retaining kinase activity even in the presence of micromolar concentrations of these compounds. 2 Since the BCR-ABL1 T315I mutation has been found to precede or accompany the progression to advanced-phase CML and anticipates failure to TKI therapy, 3 early detection of this mutant is important both from a prognostic and a therapeutic standpoint.
Current guidelines recommend KD mutation screening in patients with advanced-phase disease and in those in chronic phase (CP) who exhibit inadequate initial response or signs of loss of response. 4 At present, direct sequencing (DS) of nested PCR-amplified BCR-ABL1 products is the favored method for routine clinical use. 3 However, DS fails to reliably detect mutant clones representing 20% or less of the BCR-ABL-expressing cells. 3 More sensitive methods are therefore necessary to detect the incipient expansion of leukemic clones harboring BCR-ABL1
T315I
. One such assay involves subcloning and DNA expansion of specific clones (DESC) followed by DNA sequencing.
We evaluated the sensitivity of detection of mutation by DS and DESC in patients with CML after failure of imatinib therapy. Our results demonstrate that DESC allows for an earlier detection of BCR-ABL1 T315I than DS. The study group consisted of 62 patients with CML with resistance (n ¼ 51) or intolerance (n ¼ 11) of imatinib therapy were screened for the presence of BCR-ABL1 T315I mutation by DS before and every 3 months after the start of dasatinib on a phase I study. Screening by DESC was performed in all patients prior to and in 15 of them during dasatinib therapy. Dasatinib was administered for a median of 5 months (range, 2-13) to 10 patients carrying BCR-ABL1
. Initial dasatinib therapy consisted of 70 mg twice daily in three (one accelerated phase (AP), two blastic phase (BP)), 50 mg twice daily in four (two BP, two CP) and 35 mg twice daily in three (two CP, one BP) patients. Doses were adjusted for toxicity as previously described. 5 The complete ABL KD of the BCR-ABL allele was analyzed in patient samples using seminested reverse transcriptase PCR followed by DS as previously described. 6 DESC involved subcloning of the 0.6 kb fragment encoding for the KD after two rounds of PCR into the pGEM-T vector (Promega, Cat no. A3600). At least 10 clones containing the ABL KD were directly sequenced using an ABI377 automated sequencer. All mutations are reported in the ABL1 gene 1a orientation.
In total, 10 (15%) of 62 patients were found to carry BCR-ABL1 T315I , four prior to the start of dasatinib and six during dasatinib therapy (Table 1) . Median age was 65 years (range, 34-81). Three patients had not responded to imatinib whereas five had achieved a complete hematologic response (CHR) and two a complete cytogenetic response (CCyR). The reasons for imatinib discontinuation were hematologic resistance (n ¼ 5) and progression to AP (n ¼ 1) or BP (n ¼ 4). Of the four patients in whom BCR-ABL1 T315I was detected prior to dasatinib start, two are dead and two are alive. All four pretreatment mutants were detected by DESC. DS performed on the same samples detected BCR-ABL1 T315I only in two of them. In the two patients in whom DS failed to detect BCR-ABL1
, the percentage of clones carrying BCR-ABL1 T315I was 10 and 100%, respectively. In one of them, BCR-ABL1 T315I was detected by DS 12 months later, whereas in the other case, DS failed to detect BCR-ABL1 T315I in three separate occasions spanning 20 months. These two patients are still alive (one on hydroxyurea and one on INNO-406, the latter after having failed bosutinib) but never achieved a cytogenetic response.
BCR-ABL1 T315I was detected in six additional patients after a median time of 5 months (range, 1-6) on dasatinib, including in five of five of those analyzed by DESC and in one patient by DS in whom DESC was not available. Notably, in one of the five patients in whom BCR-ABL1 T315I was detected by DESC, this mutation was also recovered by DS more than 8 months after the DESC analysis. Of the six BCR-ABL1 T315I -positive patients during dasatinib therapy, four had no response to dasatinib and two had transient cytogenetic responses (one minor, one partial). Only one of these patients is currently alive, receiving the multikinase inhibitor KW-2449 (Figure 1 ). In one of the patients with no cytogenetic response, for whom paired samples were available, BCR-ABL1 T315I was present in 10% of clones but was not detected by DS.
Overall, the median number of clones harboring BCR-ABL1 T315I was 90% (range, 10-100%) and the median number of mutants coexpressed with BCR-ABL1 T315I was 3 (range, 1-9). DS failed to identify other 40 non-BCR-ABL1
T315I mutants, including the dasatinib resistant F317L mutation in one patient, Abbreviations: AP, accelerated phase; BP, blastic phase; CCyR, complete hematologic response; CHR, complete hematologic response; CP, chronic phase; DESC, DNA expansion of specific clones; DP, disease progression; DS, direct sequencing; HR, hematologic resistance; HU, hydroxyurea; IM, imatinib; mCyR, minor cytogenetic response; NA, not applicable; ND, not done; PCyR, partial cytogenetic response; PHR, partial hematologic response; WT, wild type. All 10 patients presented had failed imatinib therapy and received subsequent therapy with dasatinib at the indicated doses in a phase I study. *Not in CHR. The bold type signifies the T315 mutation.
Letters to the Editor regardless of the percentage of clones in which they were expressed, except for E355G, which was detected in one patient by both techniques in two separate analyses. In total, 8 of the 10 patients in whom BCR-ABL1 T315I was detected received dasatinib for more than 3 weeks and were evaluable for response. Six failed to achieve any cytogenetic response and two had transient cytogenetic responses (one minor and one partial). Seven (70%) patients died and three are alive. Of the latter, none has a cytogenetic response.
These results demonstrate that not only is DESC more sensitive than DS of PCR-amplified BCR-ABL1 products for the detection of the BCR-ABL1 T315I mutation, but also for the detection of other KD mutations known to confer resistant to either imatinib or dasatinib, such as F317L. In BCR-ABL1 T315I , the extra hydrocarbon group in the isoleucine side chain results in steric clash with imatinib and dasatinib, which interferes with binding of these compounds but not of adenosine 5'-triphosphate. 1 In this manner, BCR-ABL1 T315I confers virtually complete insensitivity to imatinib, nilotinib and dasatinib. 7 The importance of the early detection of BCR-ABL1 T315I is severalfold. First, it has been recently reported that sequential BCR-ABL1 kinase inhibitor therapy with imatinib and dasatinib may select with high frequency for BCR-ABL1
T315I as well as for other resistant compound mutants (two or more BCR-ABL1 KD mutations in the same clone) with altered oncogenic potency. 8 Second, several other screening assays with significantly higher sensitivity than DS, in addition to DESC, have been developed, including denaturing high-pressure liquid chromatography, pyrosequencing, allele-specific oligonucleotide PCR or polony assay. These methods could be streamlined for their routine use in clinical samples. Finally, and more important, several smallmolecule TKIs with activity against BCR-ABL1 T315I are currently under development. One of them, the multikinase inhibitor MK-0457, has already showed clinical activity in patients with CML harboring BCR-ABL1
. 2 In conclusion, DS has a low sensitivity of detection of ABL KD mutations, particularly when the proportion of mutated clones is small. With the advent of novel BCR-ABL1 T315I inhibitors, prompt detection of this highly resistant mutation must be prioritized and included in therapeutic algorithms. To maximize the sensitivity of BCR-ABL1 T315I detection, highly sensitive screening techniques must be incorporated into clinical practice to guide treatment decisions. Detection of the BCR-ABL1 T315I mutation in Patient 4 during dasatinib therapy. BCR-ABL1 T315I was detected by direct sequencing more than 11 months after its detection by subcloning followed by DNA sequencing of specific clones. (.) denotes bone marrow cytogenetic analysis. D, dasatinib; Hy, hydroxyurea; WT, wild type; N/A, not available.
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